BioMedNewsBreaks

WednesdayApr 22, 2026 2:34 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its ketamine ANDA, with only minor administrative updates requested. The company also reported a supportive meeting with FDA leadership aligned with federal priorities to accelerate treatments for severe mental illness, reinforcing expectations for potential approval of its preservative-free ketamine product in summer 2026. To view the full press release, visit https://ibn.fm/dL8aD About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders,…

Continue Reading

WednesdayApr 22, 2026 2:17 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Highlights AVERSA Technology on Jack Neel Podcast 

Nutriband (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan appeared on the Jack Neel Podcast to discuss the opioid crisis and the company’s AVERSA(TM) abuse-deterrent transdermal technology. The episode outlines how AVERSA(TM) is designed to reduce misuse, diversion, and accidental exposure of high-risk drugs such as fentanyl, while maintaining patient access, and is supported by a broad global patent portfolio. To view the full press release, visit https://ibn.fm/fSUKj About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into…

Continue Reading

TuesdayApr 21, 2026 2:37 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical to Biotech Success in Pharmaphorum Analysis 

Dr. Christopher J. Schaber outlines strategies for navigating constrained funding environment  Soligenix (NASDAQ: SNGX) CEO Dr. Christopher J. Schaber emphasized the importance of capital discipline in a Pharmaphorum analysis examining how biotech companies can succeed in today’s constrained funding environment, where even late-stage programs may struggle to secure investment. The article notes that strong science alone is no longer sufficient, with companies needing to align capital, execution and development strategy to achieve value-defining milestones that attract continued funding. The analysis describes capital discipline as an operating philosophy focused on directing resources toward key inflection points where data reduces uncertainty and increases program value, while also…

Continue Reading

TuesdayApr 21, 2026 2:08 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends 

Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how advancing drug pipelines are increasingly being recognized as measurable financial assets under U.S. GAAP, reflecting a broader shift in biotech valuation. The company was noted for leveraging its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio, recently valued at more than $1 billion, as an example of how scientific progress and proximity to commercialization can directly enhance balance sheet value and investor perception. To view the full press release, visit https://ibn.fm/DPVZ8 About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to…

Continue Reading

TuesdayApr 21, 2026 1:51 pm

BioMedNewsBreaks — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) Launches Ibogaine Initiative Amid U.S. Policy Shift 

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) announced the launch of its Ibogaine Initiative to expand its Health Canada-licensed GMP manufacturing platform to include ibogaine production and supply, aligning with emerging U.S. regulatory momentum to accelerate psychedelic research and patient access. The move follows a recent U.S. executive order supporting clinical development and access pathways, including IND clearance for ibogaine trials, as Optimi positions itself to meet anticipated demand with regulated, pharmaceutical-grade supply while advancing its broader global strategy in MDMA and psilocybin therapies. To view the full press release, visit https://ibn.fm/EHpKr About Optimi Health Corp. Optimi Health…

Continue Reading

MondayApr 20, 2026 3:41 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation

Oncotelic Therapeutics (OTCQB: OTLC) is featured in recent BioMedWire editorial coverage highlighting a fundamental shift in biotechnology, where scientific progress is increasingly recognized as measurable financial value rather than purely as research expenditure. As clinical-stage assets advance toward commercialization, fair-value accounting frameworks under U.S. GAAP are enabling companies to reflect pipeline progress, probability of success and timing of market entry directly on the balance sheet. Within this evolving landscape, Oncotelic exemplifies the trend through its diversified oncology pipeline and strategic holdings, including its 45% stake in GMP Bio, recently measured at an enterprise value exceeding $1 billion, demonstrating how advancing science can materially strengthen financial positioning.  The BioMedWire editorial also situates Oncotelic alongside a group…

Continue Reading

MondayApr 20, 2026 3:12 pm

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development 

NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s strategy as it advances its NRX-100 drug candidate and seeks regulatory support to address severe depression, PTSD and suicidality. To view the full press release, visit https://ibn.fm/OahNo About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for…

Continue Reading

MondayApr 20, 2026 3:00 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader  Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that early clinical trials revealed a disconnect between IV-based delivery and the daily realities of patients with chronic rare diseases, prompting a shift toward a more practical, home-based subcutaneous approach. According to Schaber, operational challenges such as travel burden, treatment scheduling, and patient retention should be…

Continue Reading

FridayApr 17, 2026 1:24 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear…

Continue Reading

FridayApr 17, 2026 12:41 pm

BioMedNewsBreaks — Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.”…

Continue Reading